nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.162	0.189	CbGbCtD
Buprenorphine—CYP3A7—Cyclosporine—focal segmental glomerulosclerosis	0.12	0.139	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Cyclosporine—focal segmental glomerulosclerosis	0.12	0.139	CbGbCtD
Buprenorphine—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.0899	0.105	CbGbCtD
Buprenorphine—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0865	0.101	CbGbCtD
Buprenorphine—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.0725	0.0843	CbGbCtD
Buprenorphine—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0603	0.0701	CbGbCtD
Buprenorphine—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0585	0.068	CbGbCtD
Buprenorphine—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0552	0.0641	CbGbCtD
Buprenorphine—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0351	0.0408	CbGbCtD
Buprenorphine—Swollen tongue—Cyclosporine—focal segmental glomerulosclerosis	0.0067	0.0501	CcSEcCtD
Buprenorphine—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.0319	CcSEcCtD
Buprenorphine—Muscle contractions involuntary—Cyclosporine—focal segmental glomerulosclerosis	0.00408	0.0305	CcSEcCtD
Buprenorphine—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00335	0.0251	CcSEcCtD
Buprenorphine—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.00251	0.0188	CcSEcCtD
Buprenorphine—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.0186	CcSEcCtD
Buprenorphine—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.00241	0.018	CcSEcCtD
Buprenorphine—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00227	0.017	CcSEcCtD
Buprenorphine—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.0168	CcSEcCtD
Buprenorphine—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00217	0.0162	CcSEcCtD
Buprenorphine—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00197	0.0147	CcSEcCtD
Buprenorphine—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.0143	CcSEcCtD
Buprenorphine—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.0142	CcSEcCtD
Buprenorphine—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.0142	CcSEcCtD
Buprenorphine—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0135	CcSEcCtD
Buprenorphine—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.0128	CcSEcCtD
Buprenorphine—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.012	CcSEcCtD
Buprenorphine—Injury—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.0116	CcSEcCtD
Buprenorphine—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00154	0.0115	CcSEcCtD
Buprenorphine—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.0114	CcSEcCtD
Buprenorphine—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.0113	CcSEcCtD
Buprenorphine—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00151	0.0113	CcSEcCtD
Buprenorphine—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.0109	CcSEcCtD
Buprenorphine—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00143	0.0107	CcSEcCtD
Buprenorphine—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.0106	CcSEcCtD
Buprenorphine—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.0105	CcSEcCtD
Buprenorphine—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.0105	CcSEcCtD
Buprenorphine—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.0101	CcSEcCtD
Buprenorphine—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.0098	CcSEcCtD
Buprenorphine—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00977	CcSEcCtD
Buprenorphine—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00966	CcSEcCtD
Buprenorphine—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00129	0.00963	CcSEcCtD
Buprenorphine—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00943	CcSEcCtD
Buprenorphine—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.00931	CcSEcCtD
Buprenorphine—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.00924	CcSEcCtD
Buprenorphine—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00909	CcSEcCtD
Buprenorphine—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00889	CcSEcCtD
Buprenorphine—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00118	0.00886	CcSEcCtD
Buprenorphine—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00859	CcSEcCtD
Buprenorphine—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00836	CcSEcCtD
Buprenorphine—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00824	CcSEcCtD
Buprenorphine—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00824	CcSEcCtD
Buprenorphine—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00822	CcSEcCtD
Buprenorphine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00801	CcSEcCtD
Buprenorphine—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00801	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.0078	CcSEcCtD
Buprenorphine—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00773	CcSEcCtD
Buprenorphine—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000992	0.00742	CcSEcCtD
Buprenorphine—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000984	0.00736	CcSEcCtD
Buprenorphine—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000982	0.00734	CcSEcCtD
Buprenorphine—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000977	0.00731	CcSEcCtD
Buprenorphine—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000972	0.00727	CcSEcCtD
Buprenorphine—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00097	0.00725	CcSEcCtD
Buprenorphine—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000953	0.00713	CcSEcCtD
Buprenorphine—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000922	0.0069	CcSEcCtD
Buprenorphine—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000918	0.00687	CcSEcCtD
Buprenorphine—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000898	0.00671	CcSEcCtD
Buprenorphine—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000892	0.00667	CcSEcCtD
Buprenorphine—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000888	0.00664	CcSEcCtD
Buprenorphine—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000867	0.00648	CcSEcCtD
Buprenorphine—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000861	0.00644	CcSEcCtD
Buprenorphine—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000849	0.00635	CcSEcCtD
Buprenorphine—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000845	0.00632	CcSEcCtD
Buprenorphine—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000843	0.00631	CcSEcCtD
Buprenorphine—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.000836	0.00626	CcSEcCtD
Buprenorphine—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000828	0.00619	CcSEcCtD
Buprenorphine—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000812	0.00607	CcSEcCtD
Buprenorphine—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000807	0.00603	CcSEcCtD
Buprenorphine—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000799	0.00598	CcSEcCtD
Buprenorphine—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000791	0.00592	CcSEcCtD
Buprenorphine—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000787	0.00589	CcSEcCtD
Buprenorphine—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000777	0.00581	CcSEcCtD
Buprenorphine—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000774	0.00579	CcSEcCtD
Buprenorphine—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000752	0.00562	CcSEcCtD
Buprenorphine—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000746	0.00558	CcSEcCtD
Buprenorphine—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000744	0.00556	CcSEcCtD
Buprenorphine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000733	0.00548	CcSEcCtD
Buprenorphine—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000733	0.00548	CcSEcCtD
Buprenorphine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000733	0.00548	CcSEcCtD
Buprenorphine—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000731	0.00546	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000728	0.00545	CcSEcCtD
Buprenorphine—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000724	0.00542	CcSEcCtD
Buprenorphine—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000717	0.00536	CcSEcCtD
Buprenorphine—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000709	0.0053	CcSEcCtD
Buprenorphine—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000703	0.00526	CcSEcCtD
Buprenorphine—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000703	0.00526	CcSEcCtD
Buprenorphine—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000698	0.00522	CcSEcCtD
Buprenorphine—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000689	0.00516	CcSEcCtD
Buprenorphine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000683	0.00511	CcSEcCtD
Buprenorphine—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000679	0.00508	CcSEcCtD
Buprenorphine—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00067	0.00501	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00064	0.00479	CcSEcCtD
Buprenorphine—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000636	0.00475	CcSEcCtD
Buprenorphine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000631	0.00472	CcSEcCtD
Buprenorphine—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000627	0.00469	CcSEcCtD
Buprenorphine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000625	0.00467	CcSEcCtD
Buprenorphine—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000619	0.00463	CcSEcCtD
Buprenorphine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000611	0.00457	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000607	0.00454	CcSEcCtD
Buprenorphine—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000606	0.00453	CcSEcCtD
Buprenorphine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000601	0.0045	CcSEcCtD
Buprenorphine—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000601	0.0045	CcSEcCtD
Buprenorphine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000579	0.00433	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000575	0.0043	CcSEcCtD
Buprenorphine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.00418	CcSEcCtD
Buprenorphine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00416	CcSEcCtD
Buprenorphine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000556	0.00416	CcSEcCtD
Buprenorphine—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000518	0.00387	CcSEcCtD
Buprenorphine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000504	0.00377	CcSEcCtD
Buprenorphine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000497	0.00372	CcSEcCtD
Buprenorphine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000481	0.0036	CcSEcCtD
Buprenorphine—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000465	0.00348	CcSEcCtD
Buprenorphine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000447	0.00334	CcSEcCtD
Buprenorphine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000443	0.00331	CcSEcCtD
Buprenorphine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000443	0.00331	CcSEcCtD
Buprenorphine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00044	0.00329	CcSEcCtD
Buprenorphine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000417	0.00312	CcSEcCtD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	2.73e-05	0.00451	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	2.69e-05	0.00444	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	2.67e-05	0.00441	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	2.67e-05	0.0044	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	2.64e-05	0.00436	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	2.57e-05	0.00424	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.57e-05	0.00424	CbGpPWpGaD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	2.5e-05	0.00412	CbGpPWpGaD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	2.46e-05	0.00405	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	2.44e-05	0.00403	CbGpPWpGaD
Buprenorphine—OPRD1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	2.36e-05	0.0039	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	2.34e-05	0.00386	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	2.34e-05	0.00386	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	2.32e-05	0.00382	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	2.31e-05	0.00381	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.28e-05	0.00376	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	2.26e-05	0.00373	CbGpPWpGaD
Buprenorphine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—focal segmental glomerulosclerosis	2.22e-05	0.00366	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	2.08e-05	0.00344	CbGpPWpGaD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	2.08e-05	0.00342	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.07e-05	0.00342	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	2.07e-05	0.00342	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	2.07e-05	0.00342	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	2.03e-05	0.00335	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	1.98e-05	0.00327	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	1.98e-05	0.00326	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	1.96e-05	0.00323	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	1.89e-05	0.00312	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.89e-05	0.00312	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	1.88e-05	0.0031	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.88e-05	0.0031	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	1.83e-05	0.00302	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	1.78e-05	0.00294	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	1.75e-05	0.00289	CbGpPWpGaD
Buprenorphine—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	1.74e-05	0.00288	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	1.72e-05	0.00284	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.72e-05	0.00284	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.69e-05	0.00279	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	1.68e-05	0.00277	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	1.65e-05	0.00272	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.58e-05	0.0026	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	1.51e-05	0.00249	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	1.51e-05	0.00249	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	1.5e-05	0.00248	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	1.49e-05	0.00246	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.49e-05	0.00246	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.44e-05	0.00238	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	1.43e-05	0.00236	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	1.41e-05	0.00233	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	1.39e-05	0.0023	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	1.36e-05	0.00225	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	1.36e-05	0.00224	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	1.32e-05	0.00218	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	1.32e-05	0.00217	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	1.31e-05	0.00216	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	1.3e-05	0.00214	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	1.28e-05	0.00211	CbGpPWpGaD
Buprenorphine—UGT1A9—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	1.27e-05	0.0021	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	1.26e-05	0.00207	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	1.25e-05	0.00207	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	1.24e-05	0.00204	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.22e-05	0.00202	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	1.2e-05	0.00197	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	1.19e-05	0.00196	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.19e-05	0.00196	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	1.17e-05	0.00194	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	1.15e-05	0.0019	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	1.14e-05	0.00188	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	1.14e-05	0.00188	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.12e-05	0.00186	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	1.11e-05	0.00184	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	1.11e-05	0.00183	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	1.1e-05	0.00182	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	1.1e-05	0.00181	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	1.06e-05	0.00175	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	1.05e-05	0.00174	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	1.05e-05	0.00173	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	1.04e-05	0.00172	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.03e-05	0.0017	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.02e-05	0.00168	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	1.01e-05	0.00167	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	1.01e-05	0.00166	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	1.01e-05	0.00166	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	1e-05	0.00165	CbGpPWpGaD
Buprenorphine—CYP2A6—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	9.81e-06	0.00162	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	9.74e-06	0.00161	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	9.61e-06	0.00159	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	9.61e-06	0.00159	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	9.54e-06	0.00157	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—LIPC—focal segmental glomerulosclerosis	9.53e-06	0.00157	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	9.39e-06	0.00155	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	9.31e-06	0.00154	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	9.15e-06	0.00151	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	8.9e-06	0.00147	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	8.84e-06	0.00146	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	8.83e-06	0.00146	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	8.54e-06	0.00141	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	8.51e-06	0.0014	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	8.45e-06	0.00139	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—CTGF—focal segmental glomerulosclerosis	8.39e-06	0.00138	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	8.12e-06	0.00134	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	8.08e-06	0.00133	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	8.06e-06	0.00133	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	8.01e-06	0.00132	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.95e-06	0.00131	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7.84e-06	0.00129	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	7.81e-06	0.00129	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	7.76e-06	0.00128	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	7.73e-06	0.00128	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.73e-06	0.00127	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—LIPC—focal segmental glomerulosclerosis	7.53e-06	0.00124	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	7.34e-06	0.00121	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	7.25e-06	0.0012	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	7.22e-06	0.00119	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	7.16e-06	0.00118	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	7.09e-06	0.00117	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	7.07e-06	0.00117	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	7.03e-06	0.00116	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7e-06	0.00115	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6.77e-06	0.00112	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	6.74e-06	0.00111	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CTGF—focal segmental glomerulosclerosis	6.63e-06	0.00109	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	6.55e-06	0.00108	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	6.44e-06	0.00106	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	6.39e-06	0.00105	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	6.38e-06	0.00105	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—LIPC—focal segmental glomerulosclerosis	6.33e-06	0.00104	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	6.19e-06	0.00102	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	6.16e-06	0.00102	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.11e-06	0.00101	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	5.99e-06	0.000988	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.98e-06	0.000987	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	5.97e-06	0.000985	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	5.94e-06	0.00098	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	5.91e-06	0.000975	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—LPL—focal segmental glomerulosclerosis	5.81e-06	0.000959	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—LIPC—focal segmental glomerulosclerosis	5.8e-06	0.000957	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	5.62e-06	0.000928	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CTGF—focal segmental glomerulosclerosis	5.57e-06	0.00092	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	5.46e-06	0.000901	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	5.45e-06	0.000899	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	5.44e-06	0.000897	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.43e-06	0.000896	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	5.4e-06	0.000891	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.22e-06	0.000862	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.18e-06	0.000855	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.14e-06	0.000847	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CTGF—focal segmental glomerulosclerosis	5.11e-06	0.000843	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.07e-06	0.000836	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.99e-06	0.000824	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AGT—focal segmental glomerulosclerosis	4.97e-06	0.00082	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.93e-06	0.000813	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.85e-06	0.0008	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.8e-06	0.000792	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.71e-06	0.000777	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	4.71e-06	0.000776	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.65e-06	0.000767	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—LPL—focal segmental glomerulosclerosis	4.59e-06	0.000758	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	4.58e-06	0.000756	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	4.58e-06	0.000755	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.57e-06	0.000753	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	4.45e-06	0.000733	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	4.42e-06	0.000729	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.34e-06	0.000715	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	4.21e-06	0.000694	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.15e-06	0.000684	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	4.03e-06	0.000665	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.01e-06	0.000661	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	3.96e-06	0.000654	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AGT—focal segmental glomerulosclerosis	3.93e-06	0.000648	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	3.9e-06	0.000643	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.87e-06	0.000639	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—LPL—focal segmental glomerulosclerosis	3.86e-06	0.000637	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ALB—focal segmental glomerulosclerosis	3.82e-06	0.000629	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.8e-06	0.000627	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.78e-06	0.000624	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.78e-06	0.000623	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.76e-06	0.00062	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.71e-06	0.000612	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.57e-06	0.000588	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.56e-06	0.000587	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—LPL—focal segmental glomerulosclerosis	3.54e-06	0.000584	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	3.54e-06	0.000584	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	3.51e-06	0.00058	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	3.49e-06	0.000576	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	3.45e-06	0.00057	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	3.34e-06	0.00055	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.33e-06	0.00055	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AGT—focal segmental glomerulosclerosis	3.31e-06	0.000545	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	3.25e-06	0.000537	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.23e-06	0.000533	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	3.23e-06	0.000532	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.22e-06	0.00053	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	3.21e-06	0.00053	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.18e-06	0.000525	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	3.12e-06	0.000514	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	3.04e-06	0.000502	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AGT—focal segmental glomerulosclerosis	3.03e-06	0.0005	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ALB—focal segmental glomerulosclerosis	3.02e-06	0.000498	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.97e-06	0.00049	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.95e-06	0.000487	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.92e-06	0.000482	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.9e-06	0.000479	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.87e-06	0.000473	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	2.87e-06	0.000473	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	2.84e-06	0.000469	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.8e-06	0.000462	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	2.79e-06	0.000461	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.76e-06	0.000455	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.64e-06	0.000435	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.62e-06	0.000432	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	2.56e-06	0.000422	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.55e-06	0.000421	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ALB—focal segmental glomerulosclerosis	2.54e-06	0.000418	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.48e-06	0.000409	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.47e-06	0.000408	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.43e-06	0.0004	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	2.42e-06	0.000399	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	2.39e-06	0.000394	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—focal segmental glomerulosclerosis	2.33e-06	0.000384	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.24e-06	0.000369	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.24e-06	0.000369	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	2.16e-06	0.000356	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	2.13e-06	0.000351	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	2.11e-06	0.000348	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.11e-06	0.000347	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	2.07e-06	0.000341	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	1.99e-06	0.000328	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	1.97e-06	0.000325	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.89e-06	0.000312	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	1.87e-06	0.000309	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	1.85e-06	0.000305	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.85e-06	0.000304	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	1.83e-06	0.000302	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	1.8e-06	0.000297	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.73e-06	0.000285	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	1.7e-06	0.00028	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	1.68e-06	0.000278	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	1.68e-06	0.000278	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	1.59e-06	0.000262	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.56e-06	0.000257	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	1.44e-06	0.000237	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	1.42e-06	0.000234	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	1.38e-06	0.000228	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	1.3e-06	0.000215	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	1.3e-06	0.000214	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	1.29e-06	0.000213	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	1.11e-06	0.000183	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	1.1e-06	0.000182	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	8.53e-07	0.000141	CbGpPWpGaD
